Likewise, abnormal expression of cyclin A2 is associated with chromosomal instability and tumor proliferation, while inhibition leads to decreased tumor growth. Therefore, CDK2 and its cyclin binding partners represent possible therapeutic targets for new cancer therapeutics. Pre-clinical models have shown preliminary success in limiting tumor growth, and have also been observed to reduce side effects of current chemotherapy drugs.
Abnormal expression of cyclin A2 is connected to chromosomal instability and tumor proliferation, while inhibition leads to slower tumor growth. Thus, CDK2 and its cyclin binding partners might serve as new therapeutic targets for cancer treatments. Preclinical models have shown that these targets can effectively limit tumor growth and reduce the side effects associated with current chemotherapy drugs.